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Background: In the absence of existing data, the present review intends to determine the incidence, prevalence
and/or genetic determinants of neonatal diabetes mellitus (NDM), with expected contribution to disease characterization.
Methods: We will include cross-sectional, cohort or case-control studies which have reported the incidence, prevalence
and/or genetic determinants of NDM between January 01, 2000 and May 31, 2016, published in English or French
languages and without any geographical limitation. PubMed and EMBASE will be extensively screened to identify
potentially eligible studies, completed by manual search. Two authors will independently screen, select studies, extract
data, and assess the risk of bias; disagreements will be resolved by consensus. Clinical heterogeneity will be investigated
by examining the design and setting (including geographic region), procedure used for genetic testing, calculation
of incidence or prevalence, and outcomes in each study. Studies found to be clinically homogeneous will be pooled
together through a random effects meta-analysis. Statistical heterogeneity will be assessed using the chi-square test
of homogeneity and quantified using the I2 statistic. In case of substantial heterogeneity, subgroup analyses will be
undertaken. Publication bias will be assessed with funnel plots, complemented with the use of Egger’s test of bias.
Discussion: This systematic review and meta-analysis is expected to draw a clear picture of phenotypic and
genotypic presentations of NDM in order to better understand the condition and adequately address challenges
in respect with its management.
Systematic review registration: PROSPERO CRD42016039765
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Neonatal diabetes mellitus (NDM) is a severe and
monogenic form of diabetes mellitus (DM) which is
characterized by the onset of insulin-requiring hyper-
glycaemia within the first months of life. NDM can be
either transient or permanent. Transient NDM presents
soon after birth and undergoes spontaneous remission
during infancy; it may however relapse to a permanent
form of DM in childhood or adolescence. Permanent* Correspondence: jobertrichie_nansseu@yahoo.fr
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(http://creativecommons.org/publicdomain/zeNDM, which accounts for 40–50 % cases of NDM, is ra-
ther a form of DM that occurs during the first 6 months
of life and does not go into remission, with patients often
presenting with failure to thrive, vomiting, dehydration,
poor feeding, hyperglycaemia and ketosis [1–7]. NDM
has been estimated to occur in 1 over 20,000 to 500,000
live births [3, 8–11], but no clear estimate is available.
The aetiology of NDM can be attributed to the missing
or disturbed development of the pancreas, reduced pan-
creatic β cell mass, disturbed β cell function or early islet
cell destruction [5].
There is strong evidence that a genetic diagnosis of
NDM improves the treatment [7]. For instance, neonates
suffering from NDM caused by a potassium channelle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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ment; hence, their clinical management can be substan-
tially improved by replacing insulin by oral agents [12].
However, traditional genetic testing for NDM will re-
quire accurate clinical information about the patient’s
phenotype to allow selection of a small number of genes
to test. Further, the selection of genes to be sequenced
will also require a predictive list based on what has usually
been registered so far. But to date, there is no existing data
that has yet compiled the phenotypic and genotypic
presentations of both forms of NDM, as well as factors
determining their occurrence. We believe that a study
addressing this issue is urgently needed, which will gen-
erate significant clinical impact in terms of a better
characterization of the disease subtypes and consequen-
tial improvement in NDM management.
Objectives
The present protocol is for a systematic review and meta-
analysis to determine the following:
– The incidence of NDM
– The prevalence of NDM
– The genetic and/or epigenetic determinants of NDM
Review questions
This review of studies published between January 01, 2000
and May 31, 2016, is designed to address the following
questions:
– What is the global incidence of NDM?
– What is the global prevalence of NDM?
– What are the genetic and/or epigenetic
determinants of NDM?
Methods
The methodology used in the present review will comply
with recommendations of the Centre for Reviews and
Dissemination guidelines released in 2009 [13]. We will
use the Preferred Reporting Items for Systematic Re-
views and Meta-Analyses (PRISMA) guidelines as the
template for reporting this review [14]. This protocolTable 1 Inclusion and exclusion criteria
Inclusion criteria
- Observational studies: cross-sectional, cohort or case-control studies
- Report on either the incidence, prevalence, genetic and/or
epigenetic determinants of NDM
- Conducted in human subjects
- Published between January 01, 2000 and May 31, 2016
- Published in English or French languages without any geographical limitati
NDM neonatal diabetes mellituswas written and presented according to the PRISMA-P
2015 guidelines [15] and registered with PROSPERO
(ID = CRD42016039765). The PRISMA-P checklist can
be found as Additional file 1.
Eligibility criteria
Peer-reviewed original reports of observational studies
(cross-sectional, cohort or case-control studies) on either
the incidence, prevalence, genetic and/or epigenetic de-
terminants of NDM will be systematically identified and
appraised. These studies must have been conducted in
human subjects, published between January 01, 2000
and May 31, 2016, and English or French languages
without any geographical limitation. Intervention studies,
letters, reviews, commentaries, editorials and reports of
less than 10 cases will not be considered for this review.
In case of duplicate reports, the most comprehensive and
up-to-date version will be included. Table 1 gives a sum-
mary of inclusion and exclusion criteria.
Information source
Publications will be identified by systematically searching
two databases: PubMed/Medline and Excerpta Medica
Database Guide (EMBASE). Literature search will be
supplemented by screening bibliographies of identified
articles and other pertinent review papers, conference
proceedings and specialist journals (by visiting their
websites).
Search strategy and study selection
We will conduct a comprehensive and extensive search
of the literature to identify all appropriate publications
available from January 01, 2000 to May 31, 2016, and
responding to our inclusion criteria. Table 2 represents
the strategy that will be used for searching PubMed.
Similarly, EMBASE will be searched using keywords
related to epidemiology, incidence, prevalence, genetics
or epigenetics and NDM.
After developing and piloting a screening guide to
make sure that inclusion criteria are adhered to and
consistently applied by all review authors, two authors
(JRNN and EVB) will independently review all retrievedExclusion criteria
- Intervention studies, letters, reviews, commentaries, editorials
and reports of less than 10 cases
- Duplicate reports (the most comprehensive and up-to-date
version will be included)
- Studies whose full data will not be accessible even after
request from the authors
on
Table 2 PubMed search strategy
Search Query Items found
#1 diabetes of the new born [Text Word] OR neonatal diabetes mellitus [MeSH Terms] OR neonatal diabetes mellitus [Text Word]
OR diabetes mellitus in the neonate [Text Word] OR diabetes mellitus in the neonate [MeSH Terms] OR infancy diabetes
mellitus [Text Word] OR permanent diabetes mellitus of infancy [Text Word] OR transient diabetes mellitus of infancy [Text
Word] OR monogenic diabetes [Text Word]
10,070
#2 Epidemiology [Text Word] OR incidence [Text Word] OR prevalence [Text Word] 1,942,690
#3 Genetic factors [Text Word] OR risk factors [Text Word] OR ABCC8 OR KCNJ11 OR INS OR GCK OR PDX1 OR epigenetics
[Text Word] OR gene expression regulation [Text Word]
1,584,221
#4 #1 AND #2 3860
#5 #1 AND #3 2587
#6 #4 OR #5 5019
#7 #6 Limits: from 2000/01/01 to 2016/05/31, and studies done in Humans 3433
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quently, for all records deemed relevant or potentially
relevant, two authors (SSNU and JRNN) will indepen-
dently assess the full-text articles for eligibility. The
Cohen’s Kappa statistic will serve to measure agree-
ment between review authors [16]. Discrepancies be-
tween review authors will be resolved by discussion and
consensus; arbitration by a third author (EVB) will be
sought whenever necessary.
Collection of data
Data abstraction will be conducted by two independent
researchers (SSNU and JRNN) using a preconceived and
standardized abstraction form. Data will be pulled out
from each study for the following variables: title, first
author, year of publication, country(ies) of origin, geo-
graphical region, objective(s) and study design, study
endpoint(s), assessment strategy, size of study popula-
tion, age of participants (range), age at diagnosis, male/
female ratio, subtype of NDM, history of consanguinity,
incidence, prevalence, associated genes, risk factors and
study conclusion(s). Disagreements between the two au-
thors will be reconciled through discussion or arbitration
by a third author (EVB).
Where only primary data (sample size/person time of
follow-up and number of cases) will be provided, these
parameters will be used to calculate the prevalence/
incidence estimate. Where prevalence/incidence rates
or relevant data for estimating them, or any other im-
portant information will not be available, the corre-
sponding author of the study will be contacted at
least twice to request the missing data.
Quality assessment
Methodological quality of studies included in the meta-
analyses will be assessed using the Newcastle-Ottawa
scales pertaining to the design of each of the studies
included [17]. Simultaneously, these instruments will be
used to make an assessment of the risk of bias affectingstudy findings. All three researchers will independently
assess the quality of studies included. The Cohen’s Kappa
coefficient will serve to calculate degree of agreement
between researchers and measure inter-rater agreement
[16]. Additionally, a thorough description of missing
data and dropouts for each included study will be pro-
vided, as well as the extent to which these missing data
could have influenced study results.
Data synthesis and analysis
Stata software v. 14 (Stata Corp, TX, USA) will serve for
data analyses. We will present a flow diagram summar-
izing the process of identification of potentially eligible
articles, with those that were subsequently excluded,
and reasons for exclusion. A table will be used to
present the main characteristics of included studies and
the outcome of quality assessment of included studies.
Summary statistics will include ranges, means (standard
deviations) or medians (interquartile ranges) and fre-
quencies (percentages) where appropriate.
Clinical heterogeneity will be investigated by examin-
ing the design and setting (including geographical re-
gion), procedure used for genetic testing, calculation of
incidence or prevalence and outcomes in each study.
Studies found to be clinically homogeneous will be
pooled in the meta-analysis. The Cochrane’s Q statistic
will be used to evaluate the presence of statistical het-
erogeneity (with a p < 0.10 being indicative of statistically
significant heterogeneity) [18]. Besides, magnitude of
statistical heterogeneity between studies will be assessed
using the I2 statistic (values of 25, 50 and 75 % will be
considered to represent low, medium and high hetero-
geneity, respectively) [19]. Where substantial heterogen-
eity will be detected, a subgroup analysis will be
performed using the following grouping variables: geo-
graphical region, assessment strategy, subtype of NDM,
age at diagnosis and study methodological quality. If the
included studies differ significantly in design, settings,
outcome measures or otherwise, we will summarize the
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assessed with funnel plots, complemented with the use
of Egger’s test of bias. Additionally, the trim-and-fill
method will be applied to assess the impact of potential
publication bias [20]. Statistically significant results will
be set at a p value <0.05.
Discussion
This systematic review and meta-analysis is expected to
draw a clear picture of phenotypic and genotypic presen-
tations of NDM in order to better understand the condi-
tion and adequately address challenges in respect with
its management. This review does not require any ethical
approval since it is based on published studies and not
individual participant data. Its results will be published in
a peer-reviewed journal and shared at relevant scientific
conferences.
Additional file
Additional file 1: PRISMA-P checklist. This document shows where the
different items required in the PRISMA guidelines for protocols appear in
the present document. (DOCX 24 kb)
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